Type II Diabetes MellitusPhase 1NCT01196728
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
A Phase 1 study testing CM3.1-AC100 in people with Type II Diabetes Mellitus, run by CellMed AG, a subsidiary of BTG plc. at 1 site in Germany.
Trial summary
The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Type II Diabetes Mellitus
- What is being tested?
- CM3.1-AC100
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteGermany
- Study dates
- Sep 2010to Nov 2010
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Provision of signed and dated informed consent prior to any study specific procedures
- Type 2 diabetes mellitus patient, diagnostically confirmed since at least 6 months
- Male or female patient aged 18 to 75 years at screening, both inclusive
- BMI >22 to ≤40 kg/m2 at screening
Who cannot join
- Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, eg Cushings's syndrome and acromegaly
- Fasting C-peptide < 500 pM at screening
- Acute gastrointestinal symptoms at the time of screening and/or Day -1
- Any clinically relevant history or the presence of cardiovascular, bronchopulmonary, gastrointestinal or neurological diseases inclusive history of chronic pancreatitis or acute pancreatitis
Trial locations and contacts
1 site in 1 country.
About this study
The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.
- Conditions
- Type II Diabetes Mellitus
- Being tested
- CM3.1-AC100
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CM3.1-AC100Drug
SAD study with single ascending subcutaneous doses
| Study group | Role | What they receive |
|---|---|---|
| CM3.1-AC100 dose A | Experimental | Compound CM3.1-AC100 s.c. Receives: Drug: CM3.1-AC100 |
| CM3.1-AC100 dose B | Experimental | Compound CM3.1-AC100 s.c. Receives: Drug: CM3.1-AC100 |
| CM3.1-AC100 dose C | Experimental | Compound CM3.1-AC100 s.c. Receives: Drug: CM3.1-AC100 |
| Placebo | Placebo comparator | Placebo for compound CM3.1-AC100 s.c. Receives: Drug: CM3.1-AC100 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety measurements
AEs, ECGs, BP, pulse, body temperature, laboratory variables, local tolerability including a VAS score for local pain, Present Nausea Intensity (PNI) by a nausea questionnaire and a VAS score of the Overall Nausea Index (ONI)
Measured: Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study
Secondary outcomes (1)
PK samples for CM3.1-AC100
Pharmacokinetics:
AUC, AUC0-4h, AUC0-t, Cmax, tmax, t1/2lz, λz, CL/F, Vz/F of CM3.1-AC100
Measured: Intense PK-sampling during the 24 hours following administration of CM3.1-AC100
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2010 (estimated)
- Study startSep 2010
- Primary completionNov 2010
- Study completionNov 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type II Diabetes MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CellMed AG, a subsidiary of BTG plc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Peter Geigle, Dr. med., Study chair, CellMed AG, a subsidiary of BTG plc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01196728
- Sponsor's protocol ID
- CellMed CM3.1-AC100/03
- Other IDs
- 2010-020895-49
- Status last verified
- Dec 2010
- First submitted
- 3 Sep 2010
- Last updated
- 6 Dec 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Dec 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT01196728
- Acronym / sponsor ID
- CellMed CM3.1-AC100/03
- Conditions
- Type II Diabetes Mellitus
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- CellMed AG, a subsidiary of BTG plc.Industry (pharma, biotech, devices)
- Study start
- Sep 2010
- Primary completion
- Nov 2010 (actual)
- Study completion
- Nov 2010 (actual)
- First posted
- 8 Sep 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to assess the safety and tolerability of the Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc) doses in patients with T2DM.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| CM3.1-AC100 dose A | Experimental | Drug: CM3.1-AC100Compound CM3.1-AC100 s.c. |
| CM3.1-AC100 dose B | Experimental | Drug: CM3.1-AC100Compound CM3.1-AC100 s.c. |
| CM3.1-AC100 dose C | Experimental | Drug: CM3.1-AC100Compound CM3.1-AC100 s.c. |
| Placebo | Placebo comparator | Drug: CM3.1-AC100Placebo for compound CM3.1-AC100 s.c. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Provision of signed and dated informed consent prior to any study specific procedures
- Type 2 diabetes mellitus patient, diagnostically confirmed since at least 6 months
- Male or female patient aged 18 to 75 years at screening, both inclusive
- BMI >22 to ≤40 kg/m2 at screening
Key exclusion criteria (4 listed)
- Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, eg Cushings's syndrome and acromegaly
- Fasting C-peptide < 500 pM at screening
- Acute gastrointestinal symptoms at the time of screening and/or Day -1
- Any clinically relevant history or the presence of cardiovascular, bronchopulmonary, gastrointestinal or neurological diseases inclusive history of chronic pancreatitis or acute pancreatitis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CM3.1-AC100SAD study with single ascending subcutaneous doses | Drug | CM3.1-AC100 dose A, CM3.1-AC100 dose B, CM3.1-AC100 dose C, Placebo |
Primary outcome
Safety measurements
Time frame: Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study
AEs, ECGs, BP, pulse, body temperature, laboratory variables, local tolerability including a VAS score for local pain, Present Nausea Intensity (PNI) by a nausea questionnaire and a VAS score of the Overall Nausea Index (ONI)
1 secondary outcome
PK samples for CM3.1-AC100
Time frame: Intense PK-sampling during the 24 hours following administration of CM3.1-AC100
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Dec 2010.
Related trials for Type II Diabetes Mellitus
Not yet recruitingObservational study
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
Active, not recruiting
The GRoceries Aimed at Increasing Nutrition Study
Type 2 Diabetes, Type II Diabetes Mellitus
RecruitingPhase 2
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Breast Cancer, Diabetes Type II
Active, not recruiting
Dietary Strategies for Remission of Type 2 Diabetes
Diabetes Mellitus, Type 2, Overweight and Obesity
Enrolling by invitation
Scaling Telehealth Models to Improve Co-morbid Diabetes and Hypertension (Phase II)
Diabetes Mellitus Type II, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Geigle, Dr. med. study chair
CellMed AG, a subsidiary of BTG plc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CM3.1-AC100 in people with Type II Diabetes Mellitus, run by CellMed AG, a subsidiary of BTG plc. at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Dec 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety measurements (time frame: Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2010; AzTrials last refreshed its copy on 28 Oct 2026.